These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7634441)

  • 41. Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis.
    Ribichini F; Ferrero V; Matullo G; Feola M; Vado A; Camilla T; Guarrera S; Carturan S; Vassanelli C; Uslenghi E; Piazza A
    Clin Sci (Lond); 2004 Oct; 107(4):381-9. PubMed ID: 15101817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1.
    Wijpkema JS; van Haelst PL; Monraats PS; Bruinenberg M; Zwinderman AH; Zijlstra F; van der Steege G; de Winter RJ; Doevendans PA; Waltenberger J; Jukema JW; Tio RA
    Pharmacogenet Genomics; 2006 May; 16(5):331-7. PubMed ID: 16609364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention.
    Toyofyuku M; Imazu M; Sumii K; Yamamoto H; Hayashi Y; Hiyama K; Kohno N
    Atherosclerosis; 2002 Feb; 160(2):339-44. PubMed ID: 11849656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene.
    Koch W; Mehilli J; von Beckerath N; Böttiger C; Schömig A; Kastrati A
    J Am Coll Cardiol; 2003 Jun; 41(11):1957-61. PubMed ID: 12798565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of angiographic and hemodynamic results of coronary balloon angioplasty on late angiographic outcome.
    Liu MW; Roubin GS; King SB
    Am Heart J; 1994 Dec; 128(6 Pt 1):1077-83. PubMed ID: 7985587
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group.
    Emanuelsson H; Beatt KJ; Bagger JP; Balcon R; Heikkilä J; Piessens J; Schaeffer M; Suryapranata H; Foegh M
    Circulation; 1995 Mar; 91(6):1689-96. PubMed ID: 7882475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and sequential angiographic follow-up six months and 10 years after successful percutaneous transluminal coronary angioplasty.
    Guiteras-Val P; Varas-Lorenzo C; Garcia-Picart J; Martí-Claramunt V; Augé-Sanpera JM
    Am J Cardiol; 1999 Mar; 83(6):868-74. PubMed ID: 10190401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E
    J Am Coll Cardiol; 2000 Mar; 35(3):592-9. PubMed ID: 10716459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans.
    Ohishi M; Ueda M; Rakugi H; Okamura A; Naruko T; Becker AE; Hiwada K; Kamitani A; Kamide K; Higaki J; Ogihara T
    Circulation; 1997 Nov; 96(10):3328-37. PubMed ID: 9396424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis.
    Bauters C; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Circulation; 1995 Nov; 92(9):2473-9. PubMed ID: 7586347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and the Risk for Restenosis After PTCA.
    Völzke H; Hertwig S; Rettig R
    Int J Angiol; 2000 Mar; 9(2):82-86. PubMed ID: 10758202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coronary angioplasty in cardiac transplant recipients.
    Swan JW; Norell M; Yacoub M; Mitchell AG; Ilsley C
    Eur Heart J; 1993 Jan; 14(1):65-70. PubMed ID: 8432294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation.
    Canosi U; Angelica Merlini P; Bernardi F; Repetto A; Bramucci E; Ferrario M; Angoli L; Gnecchi M; Ferraresi P; Marchetti G; Tavazzi L; Ardissino D
    Thromb Haemost; 2004 Apr; 91(4):795-800. PubMed ID: 15045142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies.
    Wang S; Dai Y; Chen L; Dong Z; Chen Y; Li C; Zhong X; Lin W; Zhang J
    PLoS One; 2013; 8(9):e75285. PubMed ID: 24098690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.